No matches

Rhinology

AFRS Disease Burden Infographic

This infographic highlights the clinical burden of Allergic Fungal Rhinosinusitis (AFRS), including disease severity, recurrence, complications, and impact on patients compared with CRSwNP.

10 minutes

Related resources

ADVENT On Air | Back Again: Predicting Recurrence in Chronic Rhinosinusitis with Nasal Polyps

22 min

Podcast

CRSwNP Triathlon: An Interactive Learning Experience

15 min

interactivity

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

45 min

videoanimation

The Burden in Patients with CRSwNP and Coexisting Asthma

8 min

expert video

Type 2 Inflammation and Sinonasal Barrier Dysfunction in CRSwNP

4 min

videoanimation

CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP

20 min

expert video

Loss of Smell is a Key Symptom of CRSwNP

5 min

interactivity

ADVENT on Air: OCS in CRSwNP Podcast

14 min

Podcast

Learning objectives

Recognize the key clinical features, complications, and overall burden of AFRS
Compare recurrence rates and disease impact of AFRS with CRSwNP, including pediatric considerations

Tags

CRSwNP Burden of Disease type 2 inflammation disease severity Pediatric

MAT-US-2608769 v1.0 - P 08/2026

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region

AFRS Disease Burden Infographic

Related resources

Partnering With Patients for Clinical Decision-Making in CRSwNP

Partnering With Patients: Scores That Matter in CRSwNP

Compounded Burden of Co-existing Type 2 Airway Diseases

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

CRSwNP Interactive Patient Case Tool

Assessment of Smell Loss in CRSwNP Interactive Infographic

CRSwNP MoD Video